#News: Today marks a milestone in our $23 billion US expansion plan, as we announce the opening of a state-of-the-art radioligand therapy (RLT) manufacturing facility in Carlsbad, CA. 🔗 https://t.co/ERs1BsOqpR

In Q3 2025, Novartis delivered solid sales and core operating income growth with strong pipeline progress. Our key growth drivers performed well, and we had important innovation milestone achievements including an FDA approval and positive data readout that has the potential to

On Tuesday, October 28 Novartis will announce its Q3 2025 earnings. Register to listen here: https://t.co/yLwsGTAjkB #NovartisNews $NVS $NOVN #NVSQ32025

#News: @US_FDA approval of our new oral, targeted therapy for #ChronicSpontaneousUrticaria brings new hope for patients and underlines our commitment to making bold progress in immunology. 🔗 https://t.co/B7k1qPGZu0

This #WorldHeartDay, we’re celebrating The FIT Stop event in Madrid. Inspired by the analogy of a car’s engine & the human heart, we invited citizens to partake in fun and educational activities to encourage awareness of cardiovascular health. Let’s protect our hearts & help

September is a month of reflection and momentum in #hematology – a time to recognize those affected by chronic blood cancers and disorders, and to advocate for the progress still needed so patients can live life well. 🎥 Here's how we’re driving change:

Madrid is calling and we’ve arrived for #ESCCongress! The Novartis team is on the ground and ready to engage in bold conversations, share cutting-edge science, and explore the future of cardiovascular care. Visit our full event page here. https://t.co/EPzxEwsR9e #Cardiology

Dominic Brittain, our Senior Global Program Head, CRM Development, is looking ahead to what promises to be an inspiring weekend at @escardio #ESCCongress 2025, where we’re presenting new data in cardiovascular disease.

Novartis delivered a strong Q2 25 with double-digit sales growth and core margin expansion. We advanced our pipeline, and key launches are accelerating. We upgraded our FY 25 core operating income guidance and remain confident in our mid- to long-term growth outlook.

On Thursday, July 17 Novartis will announce its Q2 2025 earnings. Register to listen here: https://t.co/OxvoXsInQI #NovartisNews $NVS $NOVN #NVSQ22025

#News: We’re excited to announce our upcoming oncology and hematology data that has been recently accepted at @ASCO Annual Meeting and @eha_hematology 2025 Congress. #ASCO25 #EHA2025. https://t.co/b8cdcALdVp

Novartis had a strong Q1 2025 with double-digit sales growth, robust margin expansion and significant pipeline progress, including 3 new product approvals. We upgraded our full-year guidance and remain focused on advancing our pipeline and achieving our growth outlook.

On Tuesday, April 29 Novartis will announce its Q1 2025 earnings. Register to listen here: https://t.co/Hu93oc4ufn #NovartisNews $NVS $NOVN #NVSQ12025

Marc’s journey from unexpected heart attacks to a life-changing diagnosis of “a genetic condition” has transformed his family's life. Learn more: https://t.co/26SeyTlffh #Novartis #NovartisLive #CVD

This FDA approval is a testament to our commitment to advancing prostate cancer care through research and innovation. Every achievement is driven by our dedication to transforming lives and giving patients what matters most – more options. #ReimaginingMedicine

Heart disease is a major health challenge in Japan. We explore Dr. Muto’s vision of a healthcare landscape that seamlessly unites human connection and digital precision to enhance patient care. Learn more: https://t.co/3XQ0HQUpNM #Novartis #NovartisLive #CVD

Cardiovascular diseases claim nearly 18 million lives annually. At Novartis, we're committed to changing this. Through innovative therapies and partnerships, we're tackling this public health challenge head-on. Learn more: https://t.co/GDa0adTKAl #Novartis #NovartisLive #CVD

Glad we got your attention! Now let’s get serious—Early detection can be a game changer in the fight against breast cancer. Know your risk, get screened. Visit https://t.co/UshzOI55of. @SusanGKomen @LivingBeyondBC @touchbbca @Breastcancerorg @sistersnetwork @knowyourlemons

#Investors: In our first full-year as a pure-play innovative medicines company, Novartis delivered stand-out FY 2024 performance delivering strong sales growth with margin expansion and achieving several key innovation milestones. https://t.co/I0e88GQ4Ap #NVSQ424

#NVSQ424 Novartis social media posts on Q4 and Full-Year 2024 results contain forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: https://t.co/zK2CK63Hi1 $NVS